123 related articles for article (PubMed ID: 38732616)
1. Blood Lead Level as Marker of Increased Risk of Ovarian Cancer in BRCA1 Carriers.
Kiljańczyk A; Matuszczak M; Marciniak W; Derkacz R; Stempa K; Baszuk P; Bryśkiewicz M; Lubiński K; Cybulski C; Dębniak T; Gronwald J; Huzarski T; Lener MR; Jakubowska A; Szwiec M; Stawicka-Niełacna M; Godlewski D; Prusaczyk A; Jasiewicz A; Kluz T; Tomiczek-Szwiec J; Kilar-Kobierzycka E; Siołek M; Wiśniowski R; Posmyk R; Jarkiewicz-Tretyn J; Sun P; Scott RJ; Narod SA; Lubiński J
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732616
[TBL] [Abstract][Full Text] [Related]
2. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
3. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Mavaddat N; Peock S; Frost D; Ellis S; Platte R; Fineberg E; Evans DG; Izatt L; Eeles RA; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Douglas F; Hodgson S; Walker L; Porteous ME; Morrison PJ; Side LE; Kennedy MJ; Houghton C; Donaldson A; Rogers MT; Dorkins H; Miedzybrodzka Z; Gregory H; Eason J; Barwell J; McCann E; Murray A; Antoniou AC; Easton DF;
J Natl Cancer Inst; 2013 Jun; 105(11):812-22. PubMed ID: 23628597
[TBL] [Abstract][Full Text] [Related]
4. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
5. Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers.
Park JS; Lee ST; Han JW; Kim TI; Nam EJ; Park HS
Clin Breast Cancer; 2018 Oct; 18(5):362-373.e1. PubMed ID: 29673794
[TBL] [Abstract][Full Text] [Related]
6. The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.
Laitman Y; Kuchenbaecker KB; Rantala J; Hogervorst F; Peock S; Godwin AK; Arason A; Kirchhoff T; Offit K; Isaacs C; Schmutzler RK; Wappenschmidt B; Nevanlinna H; Chen X; Chenevix-Trench G; Healey S; Couch F; Peterlongo P; Radice P; Nathanson KL; Caligo MA; Neuhausen SL; Ganz P; Sinilnikova OM; McGuffog L; Easton DF; Antoniou AC; Wolf I; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(3):1119-26. PubMed ID: 22212556
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Menkiszak J; Chudecka-Głaz A; Gronwald J; Cymbaluk-Płoska A; Celewicz A; Świniarska M; Wężowska M; Bedner R; Zielińska D; Tarnowska P; Jakubowicz J; Kojs Z
J Ovarian Res; 2016 Feb; 9():11. PubMed ID: 26928677
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
9. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
Couch FJ; Wang X; McGuffog L; Lee A; Olswold C; Kuchenbaecker KB; Soucy P; Fredericksen Z; Barrowdale D; Dennis J; Gaudet MM; Dicks E; Kosel M; Healey S; Sinilnikova OM; Lee A; Bacot F; Vincent D; Hogervorst FB; Peock S; Stoppa-Lyonnet D; Jakubowska A; ; Radice P; Schmutzler RK; ; Domchek SM; Piedmonte M; Singer CF; Friedman E; Thomassen M; ; Hansen TV; Neuhausen SL; Szabo CI; Blanco I; Greene MH; Karlan BY; Garber J; Phelan CM; Weitzel JN; Montagna M; Olah E; Andrulis IL; Godwin AK; Yannoukakos D; Goldgar DE; Caldes T; Nevanlinna H; Osorio A; Terry MB; Daly MB; van Rensburg EJ; Hamann U; Ramus SJ; Toland AE; Caligo MA; Olopade OI; Tung N; Claes K; Beattie MS; Southey MC; Imyanitov EN; Tischkowitz M; Janavicius R; John EM; Kwong A; Diez O; Balmaña J; Barkardottir RB; Arun BK; Rennert G; Teo SH; Ganz PA; Campbell I; van der Hout AH; van Deurzen CH; Seynaeve C; Gómez Garcia EB; van Leeuwen FE; Meijers-Heijboer HE; Gille JJ; Ausems MG; Blok MJ; Ligtenberg MJ; Rookus MA; Devilee P; Verhoef S; van Os TA; Wijnen JT; ; ; Frost D; Ellis S; Fineberg E; Platte R; Evans DG; Izatt L; Eeles RA; Adlard J; Eccles DM; Cook J; Brewer C; Douglas F; Hodgson S; Morrison PJ; Side LE; Donaldson A; Houghton C; Rogers MT; Dorkins H; Eason J; Gregory H; McCann E; Murray A; Calender A; Hardouin A; Berthet P; Delnatte C; Nogues C; Lasset C; Houdayer C; Leroux D; Rouleau E; Prieur F; Damiola F; Sobol H; Coupier I; Venat-Bouvet L; Castera L; Gauthier-Villars M; Léoné M; Pujol P; Mazoyer S; Bignon YJ; ; Złowocka-Perłowska E; Gronwald J; Lubinski J; Durda K; Jaworska K; Huzarski T; Spurdle AB; Viel A; Peissel B; Bonanni B; Melloni G; Ottini L; Papi L; Varesco L; Tibiletti MG; Peterlongo P; Volorio S; Manoukian S; Pensotti V; Arnold N; Engel C; Deissler H; Gadzicki D; Gehrig A; Kast K; Rhiem K; Meindl A; Niederacher D; Ditsch N; Plendl H; Preisler-Adams S; Engert S; Sutter C; Varon-Mateeva R; Wappenschmidt B; Weber BH; Arver B; Stenmark-Askmalm M; Loman N; Rosenquist R; Einbeigi Z; Nathanson KL; Rebbeck TR; Blank SV; Cohn DE; Rodriguez GC; Small L; Friedlander M; Bae-Jump VL; Fink-Retter A; Rappaport C; Gschwantler-Kaulich D; Pfeiler G; Tea MK; Lindor NM; Kaufman B; Shimon Paluch S; Laitman Y; Skytte AB; Gerdes AM; Pedersen IS; Moeller ST; Kruse TA; Jensen UB; Vijai J; Sarrel K; Robson M; Kauff N; Mulligan AM; Glendon G; Ozcelik H; Ejlertsen B; Nielsen FC; Jønson L; Andersen MK; Ding YC; Steele L; Foretova L; Teulé A; Lazaro C; Brunet J; Pujana MA; Mai PL; Loud JT; Walsh C; Lester J; Orsulic S; Narod SA; Herzog J; Sand SR; Tognazzo S; Agata S; Vaszko T; Weaver J; Stavropoulou AV; Buys SS; Romero A; de la Hoya M; Aittomäki K; Muranen TA; Duran M; Chung WK; Lasa A; Dorfling CM; Miron A; ; Benitez J; Senter L; Huo D; Chan SB; Sokolenko AP; Chiquette J; Tihomirova L; Friebel TM; Agnarsson BA; Lu KH; Lejbkowicz F; James PA; Hall P; Dunning AM; Tessier D; Cunningham J; Slager SL; Wang C; Hart S; Stevens K; Simard J; Pastinen T; Pankratz VS; Offit K; Easton DF; Chenevix-Trench G; Antoniou AC;
PLoS Genet; 2013; 9(3):e1003212. PubMed ID: 23544013
[TBL] [Abstract][Full Text] [Related]
11. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
Couch FJ; Gaudet MM; Antoniou AC; Ramus SJ; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; Wang X; Kirchhoff T; McGuffog L; Barrowdale D; Lee A; Healey S; Sinilnikova OM; Andrulis IL; ; Ozcelik H; Mulligan AM; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Caligo MA; von Wachenfeldt A; Barbany-Bustinza G; Loman N; Soller M; Ehrencrona H; Karlsson P; ; Nathanson KL; Rebbeck TR; Domchek SM; Jakubowska A; Lubinski J; Jaworska K; Durda K; Zlowocka E; Huzarski T; Byrski T; Gronwald J; Cybulski C; Górski B; Osorio A; Durán M; Tejada MI; Benitez J; Hamann U; Hogervorst FB; ; van Os TA; van Leeuwen FE; Meijers-Heijboer HE; Wijnen J; Blok MJ; Kets M; Hooning MJ; Oldenburg RA; Ausems MG; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Jacobs C; Eeles RA; Adlard J; Davidson R; Eccles DM; Cole T; Cook J; Paterson J; Brewer C; Douglas F; Hodgson SV; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Side LE; ; Bove B; Godwin AK; Stoppa-Lyonnet D; ; Fassy-Colcombet M; Castera L; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Bressac-de Paillerets B; Caron O; Pujol P; Coupier I; Delnatte C; Akloul L; Lynch HT; Snyder CL; Buys SS; Daly MB; Terry M; Chung WK; John EM; Miron A; Southey MC; Hopper JL; Goldgar DE; Singer CF; Rappaport C; Tea MK; Fink-Retter A; Hansen TV; Nielsen FC; Arason A; Vijai J; Shah S; Sarrel K; Robson ME; Piedmonte M; Phillips K; Basil J; Rubinstein WS; Boggess J; Wakeley K; Ewart-Toland A; Montagna M; Agata S; Imyanitov EN; Isaacs C; Janavicius R; Lazaro C; Blanco I; Feliubadalo L; Brunet J; Gayther SA; Pharoah PP; Odunsi KO; Karlan BY; Walsh CS; Olah E; Teo SH; Ganz PA; Beattie MS; van Rensburg EJ; Dorfling CM; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Heinritz W; Caldes T; de la Hoya M; Muranen TA; Nevanlinna H; Tischkowitz MD; Spurdle AB; Neuhausen SL; Ding YC; Lindor NM; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Bernard L; Viel A; Giannini G; Varesco L; Radice P; Greene MH; Mai PL; Easton DF; Chenevix-Trench G; ; Offit K; Simard J;
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):645-57. PubMed ID: 22351618
[TBL] [Abstract][Full Text] [Related]
12. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
Finkelman BS; Rubinstein WS; Friedman S; Friebel TM; Dubitsky S; Schonberger NS; Shoretz R; Singer CF; Blum JL; Tung N; Olopade OI; Weitzel JN; Lynch HT; Snyder C; Garber JE; Schildkraut J; Daly MB; Isaacs C; Pichert G; Neuhausen SL; Couch FJ; van't Veer L; Eeles R; Bancroft E; Evans DG; Ganz PA; Tomlinson GE; Narod SA; Matloff E; Domchek S; Rebbeck TR
J Clin Oncol; 2012 Apr; 30(12):1321-8. PubMed ID: 22430266
[TBL] [Abstract][Full Text] [Related]
13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Ramus SJ; Antoniou AC; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; McGuffog L; Sinilnikova OM; Healey S; Barrowdale D; Lee A; Thomassen M; Gerdes AM; Kruse TA; Jensen UB; Skytte AB; Caligo MA; Liljegren A; Lindblom A; Olsson H; Kristoffersson U; Stenmark-Askmalm M; Melin B; ; Domchek SM; Nathanson KL; Rebbeck TR; Jakubowska A; Lubinski J; Jaworska K; Durda K; Złowocka E; Gronwald J; Huzarski T; Byrski T; Cybulski C; Toloczko-Grabarek A; Osorio A; Benitez J; Duran M; Tejada MI; Hamann U; Rookus M; van Leeuwen FE; Aalfs CM; Meijers-Heijboer HE; van Asperen CJ; van Roozendaal KE; Hoogerbrugge N; Collée JM; Kriege M; van der Luijt RB; ; ; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Lalloo F; Jacobs C; Eeles R; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Paterson J; Douglas F; Brewer C; Hodgson S; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Pathak H; Godwin AK; Stoppa-Lyonnet D; Caux-Moncoutier V; de Pauw A; Gauthier-Villars M; Mazoyer S; Léoné M; Calender A; Lasset C; Bonadona V; Hardouin A; Berthet P; Bignon YJ; Uhrhammer N; Faivre L; Loustalot C; ; Buys S; Daly M; Miron A; Terry MB; Chung WK; John EM; Southey M; Goldgar D; Singer CF; Tea MK; Pfeiler G; Fink-Retter A; Hansen Tv; Ejlertsen B; Johannsson OT; Offit K; Kirchhoff T; Gaudet MM; Vijai J; Robson M; Piedmonte M; Phillips KA; Van Le L; Hoffman JS; Ewart Toland A; Montagna M; Tognazzo S; Imyanitov E; Issacs C; Janavicius R; Lazaro C; Blanco I; Tornero E; Navarro M; Moysich KB; Karlan BY; Gross J; Olah E; Vaszko T; Teo SH; Ganz PA; Beattie MS; Dorfling CM; van Rensburg EJ; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Schäfer D; Caldes T; de la Hoya M; Nevanlinna H; Aittomäki K; Plante M; Spurdle AB; ; Neuhausen SL; Ding YC; Wang X; Lindor N; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Bonanni B; Bernard L; Dolcetti R; Papi L; Ottini L; Radice P; Greene MH; Mai PL; Andrulis IL; Glendon G; Ozcelik H; ; Pharoah PD; Gayther SA; Simard J; Easton DF; Couch FJ; Chenevix-Trench G;
Hum Mutat; 2012 Apr; 33(4):690-702. PubMed ID: 22253144
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
Menkiszak J; Chudecka-Głaz A; Gronwald J; Bedner R; Cymbaluk-Płoska A; Wezowska M; Zielińska D; Rzepka-Górska I
Ginekol Pol; 2013 Sep; 84(9):758-64. PubMed ID: 24191513
[TBL] [Abstract][Full Text] [Related]
16. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
17. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Kotsopoulos J; Gronwald J; Karlan BY; Huzarski T; Tung N; Moller P; Armel S; Lynch HT; Senter L; Eisen A; Singer CF; Foulkes WD; Jacobson MR; Sun P; Lubinski J; Narod SA;
JAMA Oncol; 2018 Aug; 4(8):1059-1065. PubMed ID: 29710224
[TBL] [Abstract][Full Text] [Related]
18. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
Widschwendter M; Rosenthal AN; Philpott S; Rizzuto I; Fraser L; Hayward J; Intermaggio MP; Edlund CK; Ramus SJ; Gayther SA; Dubeau L; Fourkala EO; Zaikin A; Menon U; Jacobs IJ
Lancet Oncol; 2013 Nov; 14(12):1226-32. PubMed ID: 24140203
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Rebbeck TR; Kauff ND; Domchek SM
J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
